
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc. has raised its FY24 EPS estimate to $(0.79) from $(0.89), indicating a positive trend due to lower expenses, which highlights effective cost management efforts. The company's strategic partnership with ATEC, a significant player in the spine implant industry, is expected to enhance access to key opinion leaders and increase awareness of Aclarion's clinical technology, potentially driving revenue growth. Additionally, Aclarion's recent Q2 FY 2024 performance, where it reported an EPS of $(0.15), suggest improving financial metrics that could foster increased payer acceptance and market traction for its Nociscan platform.
Bears say
Aclarion Inc's financial outlook is negatively impacted by significantly lower-than-expected revenue performance, with quarterly revenues of $11,100 representing a 36% year-over-year decline, falling short of the forecasted $29,000. Additionally, the company continues to experience pre-commercial revenue levels, reporting $14,100 and reflecting a 24% year-over-year decrease, which indicates challenges in the market penetration of its Nociscan product. Coupled with substantial risks related to liquidity, regulatory approvals, and competitive pressures, Aclarion faces substantial hurdles in achieving sustainable growth, contributing to a bleak outlook for its financial stability.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares